Chris Lindsell Archives
Nov. 11, 2021— by Paul Govern Vanderbilt University Medical Center has joined a nationwide study to evaluate repurposed medications in the search for effective, safe treatments for mild-to-moderate COVID-19. Repurposed medications are those already approved by the U.S. Food and Drug Administration for other indications. ACTIV-6, “The Randomized Trial to Evaluate Efficacy of Repurposed Medications,” is a...
Sep. 16, 2021—Researchers at Vanderbilt have been awarded a five-year, $4 million federal grant to test whether a personalized medicine strategy will improve outcomes for patients hospitalized with acute heart failure.
Apr. 19, 2021—Vanderbilt University Medical Center (VUMC) has been named Data Coordinating Center (DCC) for a nationwide platform of studies aimed at “repurposing” existing drugs to treat mild to moderate symptoms of COVID-19.
Jan. 16, 2020—Patients in North America wait a median of three hours to receive intravenous therapy for acute heart failure, while no other region in the world waited for more than 1.2 hours, according to a global study whose lead author and co-primary investigator is Sean Collins, MD, MSc, professor of Emergency Medicine.